COMP <GO>
CNMD vs LLY // REVENUE GROWTH (YOY)
CONMED Corporation (NYSE) VS. Eli Lilly and Company (NYSE) • 15-METRIC TALLY: CNMD 4
— LLY 9
▲ REVENUE GROWTH (YOY) LEADER: LLY
LAST: $45.72 (-0.09%) • MKT CAP: $1.36B
revenue-growth
5.20%
LAST: $1,373.70 (+6.63%) • MKT CAP: $1.29T
revenue-growth
45.51%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (CNMD VS. LLY)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | CNMD | LLY | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 54.60% | 83.64% | -29.04 | LLY | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 7.80% | 32.36% | -24.56 | LLY | /roic <GO> |
| EV/EBITDA & P/E Valuation | 11.4x | 36.4x | -25.02 | CNMD | /valuation <GO> |
| Free Cash Flow Yield | 11.07% | 2.30% | +8.77 | CNMD | /fcf-yield <GO> |
| Operating Margin | 7.50% | 40.21% | -32.71 | LLY | /operating-margins <GO> |
| Net Profit Margin | 3.40% | 31.90% | -28.50 | LLY | /net-margins <GO> |
| Revenue Growth (YoY) ACTIVE | 5.20% | 45.51% | -40.31 | LLY | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 1.82% | 0.49% | +1.33 | CNMD | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 1.91 | 9.29 | -7.38 | LLY | /balance-sheet <GO> |
| Piotroski F-Score Quality | 7/9 | 9/9 | -2.00 | LLY | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | 6.77% | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 47.1 | 66.6 | -19.50 | LLY | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | 0.51 | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | 26.9x | 30.6x | -3.72 | CNMD | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $1.36B | $1.29T | -$1.29T | LLY | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | CNMD REV | LLY REV | CNMD GROSS % | LLY GROSS % | CNMD FCF | LLY FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $1.37B | $65.18B | 54.6% | 83.0% | $150.9M | $16.81B |
| FY 2024 | $1.31B | $45.04B | 56.1% | 81.3% | $153.9M | $8.82B |
| FY 2023 | $1.24B | $34.12B | — | 79.3% | $125.3M | $4.24B |
| FY 2022 | — | $28.54B | — | 76.8% | — | $7.59B |
| FY 2021 | — | $28.32B | — | 74.2% | — | $7.37B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
CNMD // BETA —
LLY // BETA 0.51